These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 3152975)

  • 1. Deferoxamine (Desferal)-induced ocular toxicity.
    Kaplinsky C; Stark B; Goshen Y; Yaniv I; Bashara S; Zaizov R
    Pediatr Hematol Oncol; 1988; 5(4):293-7. PubMed ID: 3152975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ocular and auditory toxicity of long-term, high-dose subcutaneous deferoxamine therapy.
    Orton RB; de Veber LL; Sulh HM
    Can J Ophthalmol; 1985 Jun; 20(4):153-6. PubMed ID: 4052864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deferoxamine (Desferal)-induced toxic retinal pigmentary degeneration and presumed optic neuropathy.
    Lakhanpal V; Schocket SS; Jiji R
    Ophthalmology; 1984 May; 91(5):443-51. PubMed ID: 6739047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted chronic myeloid leukemia therapy: seeking a cure.
    Fausel C
    J Manag Care Pharm; 2007 Oct; 13(8 Suppl A):8-12. PubMed ID: 17970609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Retinal pigment epithelium--desferal].
    Roulez F
    Bull Soc Belge Ophtalmol; 2007; (304):59-66. PubMed ID: 17718228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporine-induced retinal toxic blindness.
    López-Jiménez J; Sánchez A; Fernández CS; Gutiérrez C; Herrera P; Odriozola J
    Bone Marrow Transplant; 1997 Aug; 20(3):243-5. PubMed ID: 9257893
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct patterns of minimal residual disease associated with graft-versus-host disease after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
    Pichert G; Roy DC; Gonin R; Alyea EP; Bélanger R; Gyger M; Perreault C; Bonny Y; Lerra I; Murray C
    J Clin Oncol; 1995 Jul; 13(7):1704-13. PubMed ID: 7602361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Desferrioxamine-related ocular toxicity: a case report.
    Simon S; Athanasiov PA; Jain R; Raymond G; Gilhotra JS
    Indian J Ophthalmol; 2012 Jul; 60(4):315-7. PubMed ID: 22824603
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
    Spraul CW; Schicketanz C; Lang GE
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
    Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
    J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of Ph1-positive chronic myelogenous leukemia in children: comparison between allogeneic bone marrow transplantation and conventional chemotherapy. Spanish Working Party for BMT in Children (GETMON).
    Muñoz A; Bureo E; Ortega JJ; Richard C; Olivé T; Maldonado MS; Madero L; Díaz MA
    Haematologica; 1998 Nov; 83(11):981-4. PubMed ID: 9864916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence of re-appearance of BCR-ABL-positive cells years after allogeneic bone marrow transplantation for chronic-phase chronic myelogenous leukemia in patients in hematological remission.
    Diekmann L; Beelen DW; Quabeck K; Becher R; Schulte Holthausen H; Bützler R; Schaefer UW; Opalka B
    Acta Haematol; 1994; 92(4):169-75. PubMed ID: 7701913
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
    Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
    Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Allogeneic bone marrow transplantation for Philadelphia chromosome-positive chronic myelogenous leukemia in childhood.
    Lin YT; Lin DT; Jou ST; Lin KS; Lin KH
    J Formos Med Assoc; 1997 May; 96(5):320-4. PubMed ID: 9170818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
    Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
    Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Ocular toxicity of deferoxamine: description and analysis of three observations].
    Szwarcberg J; Mack G; Flament J
    J Fr Ophtalmol; 2002 Jun; 25(6):609-14. PubMed ID: 12223949
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rapid recovery with oral zinc sulphate in deferoxamine-induced presumed optic neuropathy and hearing loss.
    Pinna A; Corda L; Carta F
    J Neuroophthalmol; 2001 Mar; 21(1):32-3. PubMed ID: 11315979
    [No Abstract]   [Full Text] [Related]  

  • 19. Optical coherence tomography in desferrioxamine ocular toxicity: a place in screening and monitoring?
    Ng WS; Chandra P
    Eye (Lond); 2011 Jul; 25(7):959-61. PubMed ID: 21423137
    [No Abstract]   [Full Text] [Related]  

  • 20. Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Lange W; Herkert R; Finke J; Ragoczy U; Siegert W; Mertelsmann R; Dölken G
    Ann Hematol; 1991 Oct; 63(4):189-94. PubMed ID: 1932296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.